Nimodipine Altan Pharma

Nimodipine, the active ingredient in Nimodipine Altan Pharma, is a calcium channel blocker presented as an intravenous formulation for intravenous use. It is indicated for the prevention of cerebral vasospasm following subarachnoid hemorrhage. GNH USA supplies Nimodipine Altan Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine acts on the cerebral vasculature to prevent vasospasm after hemorrhagic events.

- Prevention of cerebral vasospasm: reduces the incidence and severity of vasospasm following subarachnoid hemorrhage, helping to maintain cerebral blood flow.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient blood pressure reduction. - Nausea or vomiting: gastrointestinal discomfort. - Flushing: warmth and redness of the skin. - Dizziness or vertigo: sensation of light‑headedness. - Peripheral edema: swelling of the extremities.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring intervention. - Bradycardia: abnormally slow heart rate. - Allergic reaction: rash, itching, or anaphylaxis. - Hepatic enzyme elevation: abnormal liver function tests. - Seizures: rare neurologic events. - Cardiac arrhythmias: irregular heart rhythms.

Use of Nimodipine requires careful clinical monitoring.

- Blood pressure monitoring: check systolic and diastolic values before and during infusion. - Cardiac assessment: evaluate heart rate and rhythm, especially in patients with pre‑existing cardiac disease. - Liver function: assess hepatic enzymes prior to therapy and periodically thereafter. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Nimodipine may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole): may increase plasma concentrations. - Other calcium channel blockers: additive vasodilatory effects leading to severe hypotension.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, beta‑blockers): monitor for excessive blood pressure reduction. - Nitrates: combined vasodilation may cause profound hypotension. - Digoxin: increased risk of bradycardia. - Diuretics: may potentiate electrolyte disturbances.